Exploring the impact of pancreatic enzyme therapy in pediatric pancreatitis: A leap toward personalized medicine

March 27 2024

Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain
A research study recently published in the American Journal of Gastroenterology explains the role of pancreatic enzyme therapy (PERT) in reducing the frequency of acute pancreatitis (AP) in children suffering from acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP). Dr. Matthew Giefer, pediatric gastroenterologist at Ochsner Children's Hospital was a contributing author for the publication.

In this retrospective cohort study, involving 356 participants—270 with ARP and 60 receiving PERT—the impact of PERT on clinical outcomes was assessed. After initiation of PERT, the mean AP annual incidence rate decreased from 3.14 down to 0.71 (p


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.